Sales of Eli Lilly diabetes drug Trulicity fall short, shares drop

Eli Lilly and Co third-quarter sales missed Wall Street estimates on Wednesday as rebates limited revenue from its top-selling diabetes drug Trulicity, and its shares fell about 4%.